Your browser doesn't support javascript.
loading
Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies.
Miano, Carmen; Romaniello, Donatella; Mazzeschi, Martina; Morselli, Alessandra; Da Pra, Silvia; Sacchi, Francesca; Bongiovanni, Chiara; Sgarzi, Michela; Pantano, Elvira; Lauriola, Mattia; D'Uva, Gabriele.
Afiliação
  • Miano C; National Laboratory of Molecular Biology and Stem Cell Engineering, National Institute of Biostructures and Biosystems (INBB), Bologna, Italy.
  • Romaniello D; Centre for Applied Biomedical Research (CRBA), University of Bologna, Bologna, Italy.
  • Mazzeschi M; Centre for Applied Biomedical Research (CRBA), University of Bologna, Bologna, Italy.
  • Morselli A; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.
  • Da Pra S; Centre for Applied Biomedical Research (CRBA), University of Bologna, Bologna, Italy.
  • Sacchi F; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.
  • Bongiovanni C; Centre for Applied Biomedical Research (CRBA), University of Bologna, Bologna, Italy.
  • Sgarzi M; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.
  • Pantano E; National Laboratory of Molecular Biology and Stem Cell Engineering, National Institute of Biostructures and Biosystems (INBB), Bologna, Italy.
  • Lauriola M; Centre for Applied Biomedical Research (CRBA), University of Bologna, Bologna, Italy.
  • D'Uva G; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.
Front Oncol ; 12: 831105, 2022.
Article em En | MEDLINE | ID: mdl-35664762

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article